ALPHAMAB ONCOLO.DL-000002 Net Asset Momentum
ALPHAMAB ONCOLO.DL-000002 net asset momentum. ALPHAMAB ONCOLO.DL-000002 (3NK) recorded a net asset momentum of -6.6% as of December 2025, with net assets of €1.71 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore capital reinvestment ratio of ALPHAMAB ONCOLO.DL-000002 to see what proportion of operating cash flow is directed to capital expenditures.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Net asset momentum of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025. This chart tracks ALPHAMAB ONCOLO.DL-000002's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is -6.6%, with net assets of €1.71 Billion EUR as of December 2025. See ALPHAMAB ONCOLO.DL-000002 shareholders equity for net asset value and shareholders' equity analysis.
ALPHAMAB ONCOLO.DL-000002 Net Asset Momentum by Year (2021–2025)
ALPHAMAB ONCOLO.DL-000002 net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see ALPHAMAB ONCOLO.DL-000002 (3NK) market capitalisation.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €1.71 Billion | €2.10 Billion | €386.17 Million | ▼ -6.6% |
| 2024 | €1.83 Billion | €2.24 Billion | €409.87 Million | ▲ +9.6% |
| 2023 | €1.67 Billion | €2.14 Billion | €465.00 Million | ▲ +7.3% |
| 2022 | €1.56 Billion | €2.12 Billion | €559.86 Million | ▼ -16.7% |
| 2021 | €1.87 Billion | €2.71 Billion | €834.80 Million | — |